Welcome to our dedicated page for Rhythm Pharmaceu news (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceu stock.
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) is a commercial-stage biopharmaceutical company whose news flow centers on rare neuroendocrine diseases and MC4R pathway–targeted therapies. The company’s updates frequently highlight global commercial performance of its lead product IMCIVREE (setmelanotide), regulatory milestones, and clinical data across multiple rare obesity indications.
Investors following RYTM news can expect regular announcements on net product revenues from global sales of IMCIVREE, including the relative contributions from the United States and international markets. Rhythm also issues press releases on reimbursement developments, such as public reimbursement agreements for IMCIVREE in Canadian provinces and under federal programs for patients with Bardet-Biedl syndrome–related obesity.
Clinical and regulatory news is a major focus. Rhythm reports on Phase 3 trials like TRANSCEND in acquired hypothalamic obesity and EMANATE in genetically caused MC4R pathway diseases, as well as exploratory and Phase 2 studies in Prader-Willi syndrome and other rare conditions. Updates often include topline efficacy and safety data, cardiometabolic outcomes, and patient- and caregiver‑reported measures presented at scientific meetings.
Regulatory communications include FDA actions on supplemental New Drug Applications, PDUFA goal dates and extensions, and EMA validation of Type II variations to existing marketing authorizations. Rhythm also provides information on development of investigational MC4R agonists bivamelagon and RM-718 and preclinical small molecules for congenital hyperinsulinism.
For users tracking RYTM, this news feed offers a centralized view of earnings releases, clinical trial readouts, regulatory decisions and access milestones related to IMCIVREE and Rhythm’s broader rare disease pipeline.
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported positive preliminary data from an exploratory Phase 2 trial of setmelanotide in Prader-Willi syndrome (PWS) with a data cut-off of Nov. 14, 2025. The 52-week trial enrolled 18 patients (ages 6–65) and remains ongoing. At Month 3 (n=8) and Month 6 (n=5), reductions in BMI and hyperphagia were observed in several patients; key highlights include 6 of 8 patients with BMI reductions at Month 3 and 6 of 7 evaluable patients with meaningful HQ-CT score reductions at Month 3. Seventeen of 18 patients remain on therapy. Safety was consistent with setmelanotide’s known profile. Rhythm plans a registrational Phase 3 trial pending completion of Phase 2 and initiated a Part D arm of RM-718 for PWS with first screening expected in Dec 2025.
Rhythm Pharmaceuticals (NASDAQ: RYTM) will disclose preliminary data from an exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS). The company will host a live conference call and webcast on Thursday, December 11, 2025 at 8:00 a.m. ET to present the update.
Participants can register for the conference call and join the live webcast via the company's Investor Relations website. An archived webcast will be posted about two hours after the call and will remain available for 30 days.
Rhythm Pharmaceuticals (Nasdaq: RYTM) presented four datasets at ObesityWeek 2025 on Nov 10, 2025 highlighting Phase 3 TRANSCEND results in acquired hypothalamic obesity. A post‑hoc TRANSCEND analysis showed a −27.1% mean placebo‑adjusted BMI reduction (p<0.0001; n=9) for patients on setmelanotide plus GLP‑1 therapy versus GLP‑1 plus placebo (n=6), and a −19.0% mean placebo‑adjusted BMI reduction (p<0.0001; setmelanotide n=72 vs placebo n=33) in patients not on GLP‑1 therapy. Presentations also reported significant improvements in cardiometabolic parameters and patient‑reported outcomes, and a separate POWER registry analysis of 212 pediatric participants examined hyperphagia and genetic variants.
Rhythm Pharmaceuticals (NASDAQ: RYTM) said the FDA extended the PDUFA goal date for the sNDA for IMCIVREE (setmelanotide) for acquired hypothalamic obesity from Dec 20, 2025 to Mar 20, 2026.
The FDA requested additional sensitivity analyses of Phase 3 efficacy data; no new data were requested and the amendment did not include safety or manufacturing information. Rhythm said it continues to collaborate with the FDA and is preparing for potential patient access.
The company will host a live conference call and webcast on Nov 7, 2025 at 8:00 a.m. ET; an archived webcast will be available about two hours after the call for 30 days.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced public reimbursement agreements for IMCIVREE (setmelanotide) in Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and with the Federal Non-Insured Health Benefits (NIHB) program for weight management in eligible patients aged 6 years and older with clinically or genetically confirmed Bardet-Biedl syndrome (BBS) and obesity.
IMCIVREE was approved by Health Canada in May 2023 after priority review and was recently added to the Common Drug List for rare diseases under Canada’s National Strategy for Drugs for Rare Diseases, supporting broader public access.
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q3 2025 net product revenue of $51.3M from global IMCIVREE (setmelanotide), a 6% sequential increase, with $38.2M (74%) from the U.S. and $13.1M (26%) outside the U.S. Rhythm announced FDA Priority Review acceptance of an sNDA for acquired hypothalamic obesity with a PDUFA goal date of December 20, 2025. Cash, cash equivalents and short-term investments were $416.1M as of September 30, 2025. Additional updates: planned preliminary Phase 2 Prader-Willi results in Q4 2025, EMA validation of a Type II variation, a one-time $3.2M France price-adjustment charge, and multiple upcoming clinical milestones into 2026.
Rhythm Pharmaceuticals (Nasdaq: RYTM) will report third quarter 2025 financial results and provide a corporate update via a live conference call and webcast on Tuesday, November 4, 2025 at 8:00 a.m. ET. Participants may register to access the live call and are advised to join 10 minutes early. Archived webcasts will be available on Rhythm's Investor Relations website for at least 30 days after the call.
Additionally, Rhythm executives will appear in two fireside chats on Wednesday, November 12, 2025: David Meeker, M.D., at the Guggenheim Healthcare Innovation Conference at 9:30 a.m. ET, and Hunter Smith with Alastair Garfield at the Stifel Healthcare Conference at 4:00 p.m. ET. Live webcasts of both events will be posted under Events and Presentations on the company website.
Rhythm Pharmaceuticals (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company specializing in rare neuroendocrine diseases, has announced its upcoming participation in two major investor conferences. David Meeker, M.D., the company's Chair, President and CEO, will engage in fireside chats at the Wells Fargo Healthcare Conference on September 3, 2025, at 9:30 a.m. ET and the Morgan Stanley Global Healthcare Conference on September 9, 2025, at 11:30 a.m. ET.
Both presentations will be available via webcast in the Investor Relations section of Rhythm's website, with replays accessible for 30 days after the events.
Rhythm Pharmaceuticals (NASDAQ:RYTM) announced significant regulatory progress for setmelanotide in treating acquired hypothalamic obesity. The FDA has accepted the company's sNDA with Priority Review, setting a PDUFA date of December 20, 2025. Additionally, the EMA validated the Type II variation submission for the same indication.
The applications are supported by the Phase 3 TRANSCEND trial results, which demonstrated a significant -19.8% placebo-adjusted reduction in BMI. The trial showed strong efficacy in both adult patients (-19.2% BMI reduction) and pediatric patients (-20.2% BMI reduction). Setmelanotide, already approved as IMCIVREE® for other rare genetic obesity conditions, was generally well-tolerated in the study.
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported strong Q2 2025 financial results, with IMCIVREE® global sales reaching $48.5 million, up 29% from Q1 2025. The company successfully raised $189.2 million through a public offering of common stock at $85 per share.
Key clinical achievements include positive Phase 2 results for bivamelagon and Phase 3 TRANSCEND trial data for setmelanotide in acquired hypothalamic obesity. The Phase 2 trial showed significant BMI reductions of 9.3% in the 600mg cohort and 7.7% in the 400mg cohort. The company plans to complete regulatory submissions for setmelanotide in acquired hypothalamic obesity to FDA and EMA in Q3 2025.
Q2 2025 resulted in a net loss of $48.0 million ($0.75 per share), compared to $33.6 million ($0.55 per share) in Q2 2024. The company projects $285-315 million in Non-GAAP Operating Expenses for 2025.